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Abstract: Our previous studies showed that alteration of dipeptides Y-Fca-Ala-OMe (III) 
into Y-Ala-Fca-OMe (IV) (Y = Ac, Boc; Fca = 1'-aminoferrocene-1-carboxylic acid) 
significantly influenced their conformational space. The novel bioconjugates Y-Fca-Pro-OMe 
(1, Y = Ac; 2, Y = Boc) and Y-Pro-Fca-OMe (3, Y = Boc; 4, Y = Ac) have been prepared 
in order to investigate the influence of proline, a well-known turn-inducer, on the 
conformational properties of small organometallic peptides with an exchanged constituent 
amino acid sequences. For this purpose, peptides 1–4 were subjected to detailed 
spectroscopic analysis (IR, NMR, CD spectroscopy) in solution. The conformation of 
peptide 3 in the solid state was determined. Furthermore, the ability of the prepared 
conjugates to inhibit the growth of estrogen receptor-responsive MCF-7 mammary 
carcinoma cells and HeLa cervical carcinoma cells was tested. 
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1. Introduction 
Peptides and proteins play crucial role in cellular signalling processes and account for numerous 
targets in medicine [1]. Despite their enormous diversity in biological function and structure, the use of 
peptides and proteins as drugs is limited due to: (i) their low metabolic stability towards proteolysis in 
the gastrointestinal tract and in serum; (ii) poor absorption after oral administration; (iii) rapid 
excretion through liver and kidneys and (iv) undesired effects caused by interaction of the 
conformationally flexible peptides with various receptors. The improvement or alteration of 
unfavourable structural and biological properties of peptide and proteins can be realized by using their 
mimetics [2]. A peptidomimetic is a peptide or non-peptide compound capable of mimicking the 
properties or biological activity of a peptide owing to the presence of secondary structure and other 
features that are analogous to those of the original peptide [2–5]. There are different approaches in the 
design and synthesis of peptidomimetics, i.e., the incorporation of the conformational constraints  
(non-peptide moieties) in order to reduce conformational flexibility, the amide bond replacement, the 
conjugation of peptides with small molecules and the backbone cyclization. 1,1'-Disubstituted 
ferrocene templates [ferrocene-1,1'-dicarboxylic acid (Fcd), ferrocene-1,1'-diamine (Fcda) and  
1'-aminoferrocene-1-carboxylic acid (Fca)] were recognized as useful and efficient  
bioorganometallic constraints designed to induce chirally organized structures upon conjugation with 
natural amino acids {Fn-[CO-(AA)m-OMe]2 (I) [6–13]}, {Fn-[NH-(AA)m-OMe]2 (II) [14,15]},  
{Y-Fca-(AA)m-OMe (III) [16–21]} and {Y-(AA)n-Fca-OMe (IV) [22]} [Fn = ferrocenylene;  
AA = amino acid; Y = di-tert-butyldicarbonate (Boc), acetamide (Ac); m = 1, 2; n = 1]. Namely, the 
introduction of the chiral peptide chains into the ferrocene scaffold enables their communication 
through intramolecular hydrogen bonds required for 3D structure formation and function of biological 
systems. Recently, Donoli et al. reported intramolecularly hydrogen-bonded series of 310-helical 
peptides of different length containing terminal ferrocenyl units and based on the strongly foldameric 
achiral α-aminoisobutyric (Aib) acid [23,24]. 
Our group demonstrated that the attachment of alanine-containing sequences at N- or C- terminus of 
Fca [25] lead to peptidomimetics III [16–21] and IV [22] able to adopt key structural features of 
protein secondary structure. Certainly, the number and position of hydrogen bond donating sites as 
well as protecting groups on the N- and C-termini strongly influenced their conformational 
preferences. The peptide III was stabilized in an interchain intramolecular manner, i.e., 9-membered 
NHFca···OCAla (IIIA) and 8-membered NHAla···OCY hydrogen-bonded rings (IIIB). Upon the 
alteration of peptides III to IV, hydrogen bonding pattern was quite perturbed. Thereat, NHFca was 
engaged in intrachain manner through contacts with hydrogen-bond-accepting acetamide carbonyl 
groups (γ-turn, IVA) or alanine nitrogen (5-membered hydrogen-bonded ring, IVB). The interchain 
IHB, a motif common for peptides III, was realized in conformer IVC through 9-membered 
NHAla···OCFca hydrogen-bonded ring (Table 1). 
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Table 1. Hydrogen bonding patterns of peptides derived from Fca and Ala (the dotted lines 
represent the hydrogen bonds). 
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* The hydrogen bonding patterns were systematized in accordance with the nomenclature of  
1,n'-disubstituted ferrocene peptides [26]. 
The present study covers the synthesis, conformational features and biological evaluation of  
Y-Fca-Pro-OMe (V) [1, Y = Ac; 2, Y = Boc] and Y-Pro-Fca-OMe (VI) [3, Y = Boc; 4, Y = Ac], 
analogues of peptides III and IV. The role of proline in the process of peptide folding, which is 
necessary to achieve the physiologically active 3D structure, is attributed to its unique structural 
properties. While the most peptide bonds exist in trans configuration to keep the side chains apart, the 
peptide imide bond that involves the NH group of the rigid five-membered pyrrolidine ring appears in 
both trans and cis forms. Cis-trans isomerization of proline-containing sequences affects numerous 
biological processes performed by peptides and proteins (cellular uptake, oligomerization, folding, 
catalysis). Furthermore, proline has been recognized as a turn inducer, e.g., proline can induce β-turns, 
especially if preceded or followed by aromatic amino acids [27–29]. 
Considering that peptide sequence and protecting groups at N- and C-terminal positions 
strongly influence the conformational features, molecular recognition, assembly and folding of small 
peptides [30], our goal is to determine the impact of proline unit on the conformational and biological 
properties of the corresponding bioorganometallics V and VI depending on amino acid sequence and 
employed protecting groups (Boc or Ac).  
2. Results and Discussion 
2.1. Chemistry 
Ac-Fca-Pro-OMe (1) and Boc-Fca-Pro-OMe (2) were prepared by coupling of N-protected Fca [25] 
with C-protected proline following the well-established procedure [16–21]. Therefore, HCl·Pro-OMe 
was treated with an excess of NEt3 to give the free base which was coupled in situ with Y-Fca-OH  
(Y = Ac, Boc), previously activated by using the standard HOBt/EDC protocol.  
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Boc-Pro-Fca-OMe (3) and Ac-Pro-Fca-OMe (4), with an exchanged sequences of the constituent 
amino acids regarding to 1 and 2, were obtained starting from Boc-Fca-OMe [25], applying the 
procedure used for the preparation of the recently described alanine analogues IV [22]. Upon  
Boc-deprotection in the presence of gaseous HCl, the resulting HCl·Fca-OMe was processed with an 
excess of NEt3 to liberate the N-terminus, followed with coupling with activated Boc-Pro-OH. The 
obtained Boc-Pro-Fca-OMe (3) was: (i) Boc-deprotected and (ii) Ac-protected upon treatment with 
acetyl chloride to give Ac-Pro-Fca-OMe (4) (Scheme 1). 
Scheme 1. Synthesis of bioconjugates 1–4. 
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Reagents and conditions: (a) NaOH/H2O, MeOH; (b) 1. EDC; HOBt, 2. HCl·Pro-OMe/Et3N;  
(c) 1. HClgas, 2. Et3N, 3. Boc-Pro-OH/EDC, HOBt; (d) 1. HClgas, 2. Et3N, 3. AcCl. 
The structural properties of the synthesized compounds were examined in solution (for 1–4) and in 
the solid state (3). The solution-phase analysis was based on the well-established strategy [16–22], i.e., 
the comparison of the spectroscopic values of a reference, a model and the new compounds. The 
monosubstituted analogues X–XII [17], unable to participate in IHBs, were selected as reference 
compounds. Since the required feature of the model substances is their structural resemblance to the 
tested compounds including the ability to form IHBs, proline-containing peptides VII–IX [31–34] and 
alanine-containing peptides III and IV [17,22] were employed as model compounds.  
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2.2. Conformational Analysis of 1–4 in Solution 
Proline-containing bioorganometallics 1–4 were examined in solution by standard spectroscopic 
techniques (IR, NMR and CD spectroscopy) to assess their hydrogen-bonding potential which is of 
crucial importance for formation of ordered structures. Therefore, the impact of the ferrocene unit on 
the conformational properties of Ac-Fca-Pro-OMe (1), Boc-Fca-Pro-OMe (2), Boc-Pro-Fca-OMe (3) 
and Ac-Pro-Fca-OMe (4) was explored by comparison of their spectral data with those corresponding 
to the model peptides Boc-Phe-Pro-OMe (VII) Boc-Pro-Gly-OMe (VIII) and Ac-Pro-Gly-OMe (IX) 
reported by Ikawa and co-workers [31–34] (to the best of our knowledge, there is no literature data on 
Ac-AA-Pro-OMe, (AA = amino acid), an analogue of Ac-Fca-Pro-OMe (1)). The required feature of 
the model compounds is their structural semblance to the analyzed compounds, including their 
hydrogen-bonding potential. Model peptides VIII and IX were found to adopt 7-membered intramolecular 
NHGly···OCNHY hydrogen-bonded ring (Y = Boc, Ac), while the NH group of phenylalanine-containing 
peptide VII was free of hydrogen-bonding interactions. 
Furthermore, we explored the influence of proline incorporated at N- or C-terminus of Fca, 
respectively, on hydrogen-bonding capability of the resulted peptides 1–4 by comparison with 
previously described alanine-containing model peptides Ac-Fca-Ala-OMe (IIIa), Boc-Fca-Ala-OMe 
(IIIb) [17], Boc-Ala-Fca-OMe (IVa) and Ac-Ala-Fca-OMe (IVb) [22]. The most stable conformations 
of IIIa and IIIb were established through interchain IHBs: NHFca···OCCOOMe (type A, 9-membered) or 
NHAla···OCNHY (type B, 8-membered ring) (Y = Boc, Ac). Their constitutional isomers IVa and IVb 
were stabilized through intrachain IHBs: NHFca···OCNHY (type A, 7-membered ring) or NHFca···NNHY 
(type B, 5-membered ring). An additional conformation C was embedded through interchain 
NHNHY···OCCOOMe IHB (9-membered ring) (Table 1). The IR spectroscopic data of model compounds 
III, IV, VII–IX is listed in Table 2. 
Table 2. IR spectroscopic data (cm−1) of model compounds III [a], IV [a], VII-IX [b]. 
Compound Formula 
νNH  
(Free) 
νNH  
(Assoc.) 
νCO  
(Ester) 
νCO  
(Amide I) 
νCO  
(Amide II) 
IIIa Ac-Fca-Ala-OMe 3434 m 3351 w 1739 s 
1682 m 
1514 m 
1657 m 
IIIb Boc-Fca-Ala-OMe 3433 m 3327 m 1731 s 
1714 s 
1518 m 
1655 m 
IVa Boc-Ala-Fca-OMe 3423 m 3324 w 1709 brs 
1557 m 
1504 m 
1536 m 
IVb Ac-Ala-Fca-OMe 3425 m 3290 w 1709 s 
1664 m 
1507 m 1562 m 
1538 m 
VII Boc-Phe-Pro-OMe ~3450 m  [c] [c] [c] 
VIII Boc-Pro-Gly-OMe ~3430 m ~3310 w [c] [c] [c] 
IX Ac-Pro-Gly-OMe ~3430 m ~3300 m [c] [c] [c] 
[a] IR spectra were recorded in CH2Cl2 (c = 5 × 10−2 M); [b] IR spectra were recorded in CDCl3  
(c = 1.25 × 10−3 M); [c] No data available.  
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2.2.1. IR Spectroscopy 
The amide NH and carbonyl stretching regions of the IR spectra of the peptides 1–4 indicate the 
presence of both associated and free states. Generally, the absorption bands below 3400 cm−1 are 
assigned to the hydrogen-bonded NH groups, while the higher absorptions are assigned to non-bonded 
NH groups. The intensification of the bands below 3400 cm−1 in IR spectra of peptides 1, 2 and 4 
suggests that the amount of their hydrogen-bonded states increases in population in comparison with 
peptide 3. Moreover, two hydrogen-bonded internal rotamers of 1, 3 and 4 are seen as two separate 
signals below 3300 cm−1 (Figure 1, Table 3).  
Table 3. IR spectroscopic data [a] (cm−1) of reference (X–XII) and goal compounds 1–4. 
Compound Formula 
νNH  
(Free) 
νNH  
(Assoc.) 
νCO  
(Ester) 
νCO  
(Amide I) 
νCO  
(Amide II) 
X Fc-COOMe   1711   
XI Fc-NHAc 3436 m   1684  
XII Fc-NHBoc 3436 m   1723  
1 Ac-Fca-Pro-OMe 3434 w 
3351 m 
3231 m 
1741 
1676  
1604 
1535 
2 Boc-Fca-Pro-OMe 3430 m 
3356 sh 
3315 m 
1741 sh 
1718  
1604 
1532 
3 Boc-Pro-Fca-OMe 
3419 sh  
3405 m 
3290 m 
3234 w 
1706 
1694  
1655 
1532 
4 Ac-Pro-Fca-OMe 3416 w 
3272 m 
3229 m 
1709 
1690  
1623 
1563 
[a] IR spectra were recorded in CH2Cl2 (c = 5 × 10−2 M). Fc = ferrocenyl,  
Fca = 1'-amino-ferrocene-1-carboxylic acid. 
In order to determine whether the associated NH groups are engaged in an intra- or intermolecular 
manner, the concentration dependence of the solution NH absorption bands was tested. Since the  
ratio of the associated and free NH bands of 1–4 revealed unaffected upon successive dilution from  
c = 5 × 10−2 M to 5 × 10−4 M, their intramolecular employment is strongly indicated (Figure 1). 
Furthermore, the ratio of hydrogen-bonded and non-bonded NH peak intensities depends on the 
employed protecting group. The bulky Boc groups of 2 and 3 interfere with hydrogen bonding and 
reduce the content of their associated NH bands.  
The carbonyl stretching frequencies indicate if the corresponding ester or amide groups are involved 
in hydrogen bonding. In order to assign the peaks observed in the carbonyl region, we compared the 
spectroscopic data of a reference and the new compounds. The corresponding monosubstituted analogues 
Fc-COOMe (X), Fc-NHAc (XI) and Fc-NHBoc (XII) (Fc = ferrocenyl) [17] served as a reference 
compounds due to their inability to form intramolecular hydrogen bonds (IHBs) (Table 3).  
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Figure 1. The NH stretching vibrations in concentration-dependent IR spectra of 1–4 in 
CH2Cl2 (solid line: c = 5 × 10−2 M, dashed line: c = 5 × 10−4 M). 
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Since the carbonyl stretches of esters 1 and 2 at 1741 cm−1 correspond to the bands of associated 
model esters III, their engagement in hydrogen bonding is indicated. Contrarily, the carbonyl 
stretching absorptions of esters 3 and 4 that are correlated to those of non-bonded esters IV and X, 
indicate their non-involvement in hydrogen-bonding. Considering that hydrogen-bond-accepting 
urethane [30,35,36] and acetamide group [19] absorb at lower wavenumbers, the urethane carbonyl 
group of Boc-Pro-Fca-OMe (3) and acetamide carbonyl group of Ac-Pro-Fca-OMe (4), registered 
around 1690 cm−1, are expected to participate in hydrogen bonding. Boc and Ac carbonyl groups, 
attached at upper cyclopentadienyl ring (Cp) of Ac-Fca-Pro-OMe (1) and Boc-Fca-Pro-OMe (2), are 
precluded from participating in IHBs because of the unavailability of hydrogen-bonding-donating 
groups at the lower Cp ring. Therefore, their absorption frequencies are correlated with those belonging 
to the hydrogen-bonding free XI and XII (Table 3).  
2.2.2. NMR Spectroscopy 
The hydrogen bonding engagement of the bioconjugates 1–4, strongly indicated by the 
corresponding NH stretching absorptions below 3400 cm−1, was corroborated by the downfield shifts 
(δ > 7 ppm) of their NH groups in non-polar CDCl3. Certainly, the hydrogen-bonded NH groups of the 
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previously described model compounds III, IV and VII–IX were found to resonate downfield in 
similar positions, while NH groups of the HB-free reference compounds XI and XII were upfield 
shifted (Table 4). 
Table 4. 1H-NMR chemical shifts [a] of the NH protons (ppm) of a model (III, IV,  
VII-IX), a reference (XI, XII) and the goal compounds 1–4. The proposed IHB patterns of 
a model and a reference compounds VII-XVI. The possible IHB patterns of the goal 
compounds 1–4. 
Compound Formula 
δ/ppm 
(NHAA) [b] 
δ/ppm 
(NHFca/Fc) 
IHB Pattern IHB Ring Size 
IIIa Ac-Fca-Ala-OMe 6.71 7.93 
NHFca···OCAla 9-membered 
NHAla···OCAc 8-membered 
IIIb Boc-Fca-Ala-OMe 6.77 6.40 
NHFca···OCAla 9-membered 
NHAla···OCBoc 8-membered 
IVa Boc-Ala-Fca-OMe 5.14 7.64 
NHFca···NAla 5-membered 
NHAla···OCFca 9-membered 
IVb Ac-Ala-Fca-OMe 6.41 8.04 
NHFca···OCAc 7-membered 
NHFca···NAla 5-membered 
NHAla···OCFca 9-membered 
VII Boc-Phe-Pro-OMe [c]  [d]  
VIII Ac-Pro-Gly-OMe 
7.25(t) 
 NHGly···OCAc 7-membered 6.23(c) 
IX Boc-Pro-Gly-OMe 
7.28(t) 
 NHGly···OCBoc 7-membered 6.49(c) 
XI Fc-NHAc  6.49 [d]  
XII Fc-NHBoc  5.55 [d]  
1 Ac-Fca-Pro-OMe [e]  
8.23(t) 
NHFca···OCPro 9-membered 8.38(c) 
2 Boc-Fca-Pro-OMe [e]  
7.12(t) 
NHFca···OCPro 9-membered 6.80(c) 
3 Boc-Pro-Fca-OMe [e]  
8.78(t) 
NHFca···OCPro 7-membered 7.53(c) 
4 Ac-Pro-Fca-OMe [e]  
8.81(t) 
NHFca···OCPro 7-membered 7.29(c) 
[a] NMR spectra were measured in CDCl3 (c = 5 × 10−2 M); [b] AA = natural amino acid; [c] No data available; 
[d] IHB was not indicated; [e] The occurrence of both isomers [(c) = cis, (t) = trans] in solution at 298 K is 
confirmed by 13C-NMR on the basis of the well-documented shift differences observed for Cβ- and  
Cγ-atoms [37,38]. 
The goal of this paper was to determine the conformational consequences of: (i) the replacement of 
natural amino acid (phenylalanine or glycine) belonging to the model proline-containing peptides  
VII–IX with bioorganometallic amino acid (Fca) and (ii) the replacement of alanine units of  
Fca-containing model peptides III and IV with proline. Due to the lack of an amide hydrogen, proline 
residues of 1–4 are not able to donate hydrogen bonding. Their possible involvement in hydrogen 
bonding might be realized through inter- (9-membered) or intrachain (7-membered) IHB rings  
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upon accepting NHFca (Table 4). Considering that the model peptides III, IV and VII–IX were 
stabilized through IHBs, the expected IHB patterns of the novel peptides 1–4 were explored by 
concentration- and temperature-dependent NMR analyses. The considerable changes in chemical shifts 
(Δδ = 1–4 ppm) upon dilution or heating are expected for intermolecular hydrogen bonding. Since the 
successive decreasing of concentration (50–6.25 mM) did not cause any discernible changes in 
chemical shifts of amide protons, the intramolecular hydrogen bonds, proposed by IR experiments, 
were corroborated (Figure 2). Furthermore, the results of temperature-dependent NMR spectroscopy 
were in accordance with these findings. The examined conjugates 1–4 demonstrated negligible 
dependence of the chemical shifts (Δδ < 0.7 ppm) on temperature (Figure 3).  
Figure 2. Concentration dependent NHtrans chemical shifts of peptides 1–4. [1H-NMR 
measurements were performed for a series of 6.25, 12.5, 25 and 50 mM solutions]. 
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Figure 3. Temperature dependent NHtrans chemical shifts of peptides 1–4 (c = 2.5 × 10−2 M) 
in the temperature range of 258–328 K. 
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The measurements of the temperature dependences of chemical shifts (Δδ/ΔT) in hydrogen bonding 
solvents enable differentiation of the solvent-exposed and solvent-shielded peptide NH groups [39–45]. 
Since DMSO causes rapid decomposition of ferrocene peptides, their temperature dependences were 
determined in CDCl3 solution [22,46,47]. Generally, the law Δδ/ΔT values (−2.4 ± 0.5 ppb/K) are 
measured for both exposed and shielded amide protons of short peptides. The larger temperature 
dependencies are characteristic for NH groups which were shielded from solvent at starting state, but 
became exposed through dissociation of the self-associated aggregates or unfolding of ordered 
conformations at increased temperatures [48]. Accordingly, larger temperature dependencies of 
concentration-independent amide protons of 1–4 emanate from the initially shielded species switched to 
the unshielded environment by unfolding of conformations organized through IHBs (Figure 3). 
Polarity and hydrogen bonding potency of a solvent are of outstanding significance in the 
evaluation of hydrogen bond strength. Owing to its accepting capability, DMSO disrupts peptide 
hydrogen bonds causing the unfolding of ordered structures [49]. Taking that in consideration, the 
strength of IHBs indicated by the results of IR and NMR analyses was explored by DMSO titration 
experiments (Figure 4) [16–22,50]. The highest chemical shift value of NHFca belonging to  
Ac-Pro-Fca-OMe (4) and the lowest chemical shift alteration upon addition of DMSO (Δδ = 0.42 ppm) 
indicate its engagement in a strong IHB. A similar behaviour in DMSO experienced amide protons of 
Ac-Fca-Pro-OMe [1, (Δδ = 0.85 ppm)] and Boc-Pro-Fca-OMe [3, (Δδ = 0.73 ppm)] suggesting their 
participation in IHBs of medium strength. Contrarily, upfield shifting (δ = 7.12 ppm) and the highest 
chemical shift variation (Δδ = 1.12 ppm) of NHFca belonging to Boc-Fca-Pro-OMe (2) indicate its 
involvement in weak IHB.  
Figure 4. Solvent dependence of NHtrans chemical shifts at varying concentrations of 
DMSO in CDCl3 (c = 2.5 × 10−2 M, 298 K) to probe exposed vs. hydrogen-bonded amides. 
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The IHB patterns of peptides 1–4, proposed by IR and 1H-NMR analyses (Table 4), are supported 
by their NOESY spectra. The interchain NOE contacts between amide protons of Fca and proline 
belonging CHα and COOMe protons strongly support the proposed 9-membered NHFca···OCPro IHB 
rings in peptides 1 and 2 (Table 4, Figure 5).  
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Figure 5. The proposed IHBs in peptides 1 (a) and 2 (c) are depicted with dashed lines and 
the interchain NOE connectivities are presented with arrows; the interchain NOE 
connectivities between the C- and N-termini of 1 (b) and 2 (d) are depicted with dashed lines.  
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2 (Boc-Fca-Pro-OMe)  
  
PPM (F2) 7.60 7.50 7.40 7.30 7.20 7.10 7.00 6.90 6.80 6.70 
PPM (F1)
7.2 
6.8 
6.4 
6.0 
5.6 
5.2 
4.8 
4.4 
4.0 
3.6 
3.2 
NH Fca 
CH D Pro 
COOMe 
CH Fc 
(c) (d) 
Furthermore, NOE contacts of amide protons of Fca within the peptide chain attached at upper Cp 
of 3 and 4, promote the suggested intrachain NHFca···OCPro IHBs (γ-turn) (Table 4, Figure 6). NMR 
investigations of the solvent influence on the cis-trans isomerization of small peptides [51–59] revealed 
the increased fraction of the trans form in less polar or non-polar solvents. It was also found that 
intramolecular hydrogen bonds are consistent with the trans form [60]. Multiple resonances detected 
for the same proton during the course of NMR analysis are attributed to the presence of rotamers  
if the rate of the interconversion (e.g., amide cis-trans isomerization) is slow relative to the NMR  
scale [37,40,61]. On heating, isomerization rate increases causing the coalescence of signals. The fully 
coalesced peaks at higher temperatures correspond to the weighted average chemical shift value for the 
two conformers on the NMR timescale. Contrary, slow proline isomerization at higher temperatures 
reveals the peaks resolved due to the persistence of cis and trans conformers at NMR timescale [62–65].  
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Figure 6. The proposed IHBs in peptides 3 (a) and 4 (c) are depicted with dashed lines and 
the intrachain NOE connectivities are presented with arrows; the intrachain NOE 
connectivities of 3 (b) and 4 (d) are depicted with dashed lines.  
Fe
N
H
O
OMe
O
N OtBu
O
3 (Boc-Pro-Fca-OMe)  
  
PPM (F2) 8.76 8.72 8.68 8.64 8.60 8.56 8.52 8.48 8.44 8.40 8.36 8.32 
PPM (F1
8.4 
8.0 
7.6 
7.2 
6.8 
6.4 
6.0 
5.6 
5.2 
4.8 
4.4 
4.0 
3.6 
3.2 
2.8 
2.4 
2.0 
1.6 
NH Fca 
CH D Pro 
CH 3Boc 
(a) (b) 
Fe
N
H
O
OMe
O
N Me
O
4 (Ac-Pro-Fca-OMe)  
  
PPM (F2) 8.4 8.0 7.6 7.2 6.8 6.4 6.0 5.6 5.2 4.8 4.4 4.0 3.6 3.2 2.8 2.4 
PPM (F1)
9.00 
8.96 
8.92 
8.88 
8.84 
8.80 
8.76 
8.72 
8.68 
8.64 
8.60 
8.56 
8.52 
Works 3: L. Barisic 2602 50 mM 
NH Fca 
CH D Pro CH Fc 
CH 3Ac + CH J Pro 
(c) (d) 
The NMR spectra recorded at: (i) decreased temperatures and (ii) an increased amount of DMSO, 
respectively, identified the cis and trans isomers of the new peptides 1–4. The trans:cis ratio was 
calculated from integrated intensities of the appropriate resonances. Upon heating to 328 K, the two 
peaks of the trans and cis isomers of 1–4 coalesced into a single peak due to the medium 
(compound 3) and rapid (compounds 1, 2 and 4) isomerization. In DMSO, peptides 3 and 4 underwent 
to slow or medium isomerization, respectively, while peptide 1 displayed rapid isomerization. 
Completely coalesced amide resonances of peptide 2 upon titration with DMSO reflect the average 
chemical shift of rapidly exchanged cis and trans rotamers as a consequence of weak IHB ineligible to 
induce isomer locking. In contrast, the abundance of the trans amide in peptide 4 is attributed to its 
stabilization through stronger IHB in comparison to those proposed for the bioconjugates 1–3  
(Table 5). These finding are consistent with the above-mentioned conclusions [51–65] concerning the 
cis-trans isomerization of a proline imide bond of small peptides.  
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Table 5. The trans-cis ratios of imide bonds of peptides 1–4 measured by 1H-NMR. 
Ac-Fca-Pro-OMe (1) 
T (K) [a] DMSO (%) [b] 
Boc-Fca-Pro-OMe (2) 
T (K) [a] DMSO (%) [b] 
228 328 0 36 228 328 0 36 
δ (ppm) 
cis 8.67 
8.04 
8.39 9.00 
δ (ppm) 
cis 7.14 
6.83 
6.80 
7.99 
trans 8.51 8.23 8.92 trans 7.57 7.13 
trans:cis 90:10  91:9 90:10 trans:cis 90:10  93:7  
Boc-Pro-Fca-OMe (3) 
T (K) DMSO (%) [a] 
Ac-Pro-Fca-OMe (4) 
T (K) DMSO (%) [a] 
228 328 0 36 228 328 0 36 
δ (ppm) 
cis 7.38 
8.21 8.53 
9.00 
δ (ppm) 
cis 7.63 
8.72 
7.29 9.41 
trans 8.67 9.10 trans 8.98 8.81 9.21 
trans:cis 66:33   56:44 trans:cis 94:6  93:7 74:26 
[a] The temperature-dependent NMR spectra were measured in CDCl3 (c = 2.5 × 10−2 M); [b] 1H NMR titration 
of CDCl3 solutions of 1–4 (c = 2.5 × 10−2 M) with DMSO was performed at 298 K. 
2.2.3. CD Spectroscopy 
Circular dichroism is a valuable tool for evaluating the secondary structure, folding and binding 
properties of proteins [66]. The insertion of ferrocene into the chiral peptide environment induces 
Cotton effect in the region of ferrocene-based transitions around 480 nm owing to an ordered 
structures driven by hydrogen bonding between podand peptide chains [6–13,16–22] or within the 
same peptide chain [12,67]. Furthermore, it was shown that the sign of the CD signal of ferrocene 
peptides (which reflects an average of the entire molecular population) is influenced by the sequence 
of the natural peptide fragment [17,19,68], the type of N-protected groups attached at ferrocene 
core [19] and the type of the employed solvent [17,19].  
Although the proposed hydrogen bonding patterns for peptides 1 and 2 are very similar, their CD 
spectra are quite different due to chromophoric reorientation induced by hydrogen bonding in the 
presence of different protecting groups [69]. The different intensities of the Cotton effects in the CD 
spectra of the bioconjugates 1–4 indicate the different levels of chiral organization. The absolute 
values of Cotton effects of 2–4, ranged between 500 and 1,000 deg·cm2·dmol−1, are in a good 
agreement with previously described alanine analogues III [17] and IV [22]. The increased  
CD-activity of peptide 1 indicates higher level of chiral organization established through interchain 
NHFca···OCCOOMe IHB (Figure 7). Moreover, the CD-silent ferrocene region in the spectrum of peptide 
2, obtained upon titration with DMSO, is attributed to the loss of the chiral organization owing to the 
cleavage of weak IHB. The decreasing of the CD intensity in a strong hydrogen-bond forming solvent, 
demonstrated herein for peptides 1 and 4, has also been shown for previously described ferrocene 
peptides [16,19,20]. However, the addition of DMSO to CH2Cl2 solution of 3 caused the increment of 
the CD signal. This exception, reported for the several ferrocene ureidopeptides by Heinze et al. arose 
from substantial alteration of the chromophore setting of the examined peptide in CH2Cl2 and 
CH2Cl2/DMSO. Heinze reached the conclusion that the solvent dependent Cotton effects observed are 
greatly influenced by other ordering phenomena, while the stable conformations established through 
IHBs in non-polar solvents have only a minor influence [47]. 
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Figure 7. The Cotton effects in chirality-organized ferrocene peptides 1 and 2 (a) and 3 and 
4 (b) in CH2Cl2 (c = 5 × 10−3 M) and CH2Cl2 (c = 5 × 10−3 M) containing 20% of DMSO.  
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2.2.4. Crystal Structure of Boc-Pro-Fca-OMe (3) 
Single crystal X-ray diffraction confirmed existence of an intrachain hydrogen bond in  
Boc-Pro-Fca-OMe (3) which was established by NMR spectroscopy. Conformation of the compound 
is stabilised by one N-H···O and four weak C-H···O intramolecular hydrogen bonds (Figure 8, Table 6). 
An additional stabilization is achieved through interchain dipolar interaction between a carbonyl group 
bound to one Cp ring and NH group bound to another Cp ring (Figure 9): the covalent bonds are 
approximately parallel (torsion angle between them being 5.9°), and distance between their midpoints 
is 3.33 Å. However, there are no intermolecular hydrogen bonds present, so the packing is dominated 
by dispersion interactions, only. 
Figure 8. Conformation of Boc-Pro-Fca-OMe (3) in the crystal stabilised by intrachain 
intramolecular hydrogen bonding.  
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Table 6. Geometric parameters of hydrogen bonding. 
D–H···A D–H/Å H···A/Å D···A/Å D–H···A/° Symm. op. on A 
N1–H1···O2 0.86 2.10 2.810(10) 139 x, y, z 
C2–H2···O1 0.93 2.46 2.906(12) 110 x, y, z 
C8–H8B···O1 0.97 2.47 2.827(14) 101 x, y, z 
C13–H13C···O2 0.96 2.37 2.969(14) 120 x, y, z 
C15–H15C···O2 0.96 2.45 3.031(16) 119 x, y, z 
Figure 9. An additional stabilization of Boc-Pro-Fca-OMe (3) through interchain 
intramolecular dipolar interaction between CO and NH groups.  
 
2.3. Biological Evaluation of Bioconjugates 1–4 
The use of peptidomimetics is one of the most recent methods of drug design and development in 
medicinal chemistry due to various types of pharmacological activities displayed by them. Due to their 
versatile activities (antimicrobial, anticancer, antiviral, antimalarial, antioxidant, immunosuppressive 
activity, immunodetection, selectivity for DNA receptors etc. [70]), peptidomimetics are utilized to 
design and develop novel drug molecules which can be effective in the treatment of various human 
diseases. Since cancer is considered as the most serious health problem all over the world, the 
discovery of new potent, safe and selective antitumor agents is strongly needed. Peptidomimetics have 
potential as antitumor agents due to their anti-cancer activity reported in the literature. For example, 
anticancer peptidomimetics can bind to target proteins and induce cancer cells to enter apoptotic cell 
death by mimicking key interactions that activate apoptotic pathway in the specified cells [71]. Also, 
Liao et al. synthesized novel unnatural amino acid-substituted (hydroxyethyl)urea peptidomimetics 
which inhibited secretase and interfered with the malignancy of neuroblastomas and therefore showed 
that these peptidomimetics can be used as lead compounds for further development of novel anticancer 
drugs [72]. 
U.S. National Cancer Institute (NCI) phased out its murine leukemia P388 anticancer drug 
screening program in 1990 and developed in vitro primary screen based upon a panel of 60 different 
human tumor cell lines [73]. Only in first five years of that program 30,000 compounds involved in 
cancer researches worldwide have been tested according to NCI screen. Compounds interesting as 
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potential anticancer drug are being tested over a defined range of concentrations to determine the 
relative degree of growth inhibition or cytotoxicity against each cell line.  
In the ongoing research, evaluation of biological activity of novel Fca and proline conjugates 1–4 
was done against human tumour cell lines. Since conventional anticancer drug discovery and 
development is focused on the search for cytotoxic agents by this preliminary in vitro screen we aimed 
to determine potential of compounds 1–4 as cytotoxic i.e., antitumor agents.  
The biological activity of peptides 1–4, with emphasis to possible anti-cancer activity, was tested  
in vitro and evaluated on the basis of their ability to inhibit growth of MCF-7 mammary carcinoma 
cells and HeLa cervical carcinoma cells. Cytotoxicity of the synthesized compounds was assessed on 
the basis of in vitro growth in 96-well plates measured by cell-mediated reduction of tetrazolium salt 
WST-1 and the results are expressed as cell viability (%) and presented in Figure 10.  
Figure 10. Effects of four different compounds on MCF-7 (a) and HeLa (b) cells viability 
assessed by the WST-1 assay. Values were represented as the mean ± SD from three 
independent experiments. 
 
(a) 
 
(b) 
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Compound 3 does not possess antiproliferative potential toward MCF-7 cell line, while other tested 
compounds showed some potential to inhibit growth of MCF-7 cells (Figure 10a). The 50% inhibition 
of cell growth was not detected by the compounds 1, 3 and 4 in the range of tested concentrations  
(1–500 µM) and therefore their IC50 values are considered to be higher than 500 µM. The highest 
cytotoxicity in MCF-7 cells is obtained by compound 2 with IC50 value of 357.72 µM. Similar results 
were obtained with HeLa cells (Figure 10b). The trend of cytotoxicity is the same as in MCF-7 cells; 
the weakest effect was provoked by compound 3 and the most pronounced inhibition of HeLa cells 
growth was observed in the treatment with a compound 2. The compounds 1, 2 and 4 have resulted 
with 50% inhibition of cell growth after the 72-hour treatment and therefore IC50 values for HeLa cells 
were calculated to be: 474.99 µM (compound 1), 463.64 µM (compound 4) and 203.27 µM 
(compound 2). Considering that the peptide 2 is stabilized by the weakest IHB in comparison with 
conjugates 1, 3 and 4, these results are quite unexpected. But, having in mind that polarity or 
lipophilicity of the compound is a prerequisite for potential pharmaceutical applications, the obtained 
results might be attributed to the increased lipophilicity of peptide 2 (Rf = 0.50) with regard to more 
polar analogues 1 (Rf = 0.30), 3 (Rf = 0.33) and 4 (Rf = 0.22). Obtained IC50 values are relatively high 
when compared with compounds with well known anti-cancer activity, like doxorubicine or cisplatin, 
as the reference drugs. IC50 values for doxorubicin and cisplatin determined in different human cancer 
cell lines and obtained from literature survey varies mostly from 0.1 µM to 15 µM [74,75] depending 
on cell type. Since previously described conjugates of Fca with amino acids had not been subjected to 
biological evaluation, we were not able to explore how the introduction of proline into conjugates 1–4 
influences the cytotoxicity of this class of peptidomimetics. The obtained results on cytotoxic activity 
of herein described bioorganometallics 1–4 represents the initial step in the future investigation of 
ferrocene-containing peptidomimetics. 
Therefore, peptide 2, which exibited the highest inhibitory effect among tested bioconjugates 
actually has poor cytotoxic activity toward MCF-7 and HeLa cells and can not be considered as 
potential anticancer drug candidate. Nevertheless, the obtained results are valuable as a guide how to 
further direct the synthesis of similar analogues with improved biological properties. 
The cells were daily examined by inverted light microscopy to observe if there are any visible 
morphological changes in MCF-7 cells. After treatment with synthesized compounds, cells were 
stained with crystal-violet and photographed (Figure 11).  
Figure 11. Light microscopy of MCF-7 cells stained with cystal-violet after 72 h of 
treatment with tested compounds 1–4. Control cells (a) and cells treated with 500 µM  
1 (b); 2 (c); 3 (d) and 4 (e). Magnification 400×. 
 
Exposure to the highest concentration of the tested compounds 1–4 (500 µM) for 72 h resulted in 
reduction of cell number and decreased monolayer density (Figure 11b–e) when compared to control 
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MCF-7 cells (Figure 11a) which were well attached and has typical epithelial morphology. Evidently, 
the proliferation of the MCF-7 cancer cell was inhibited by the testing compounds in vitro and 
observed morphological changes correspond with obtained cytotoxicity results, but further 
investigation is needed to explore possible mechanism of action and type of cell death. 
3. Experimental Section  
3.1. General Information 
The syntheses were carried out under argon. The CH2Cl2 used for synthesis and FTIR was dried 
(P2O5), distilled over CaH2, and stored over molecular sieves (4 Å). EDC (Acros Organics, Geel, 
Belgium), HOBt (Aldrich, Schnelldorf, Germany), acetyl chloride (Aldrich, Schnelldorf, Germany) 
and proline (Acros Organics, Geel, Belgium), were used as received. The syntheses of Y-Fca-OMe and 
Y-Fca-OH have been previously described [16–21,25]. The protection of N- or C-termini of proline 
was carried out by using sodium hydroxide, aqueous dioxane and di-tert-butyldicarbonate to give  
Boc-Pro-OH or gaseous HCl in MeOH to obtain HCl·Pro-OMe. Products were purified by preparative 
thin layer chromatography on silica gel (Kieselgel 60 HF254, Merck, Darmstadt, Germany) by using 
CH2Cl2 or mixture EtOAc/CH2Cl2 as eluents. Infrared spectra were recorded as CH2Cl2 solutions 
between NaCl windows by using a Bomem MB 100 mid FTIR spectrometer. (m) = medium,  
(w) = weak, (sh) = shoulder. The 1H and 13C NMR spectra were recorded at 600 MHz on Bruker 
Avance spectrometer and were referenced to the residual solvent peak (CDCl3, 1H: 7.26 ppm, 13C: 
77.16 ppm). In the case of the CDCl3/d6-DMSO mixture, the calibration was done using Me4Si as 
internal standard due to the overlapping of the residual solvent peak of d6-DMSO with proline peaks. 
Double resonance experiments (COSY, NOESY and HMBC) were performed in order to assist in 
signal assignment. (s) = singlet, (d) = doublet, (m) = multiplet or (br) = broad. Unless otherwise noted, 
all spectra were recorded at 298 K. CD spectra were recorded using a Jasco-810 spectropolarimeter in 
CH2Cl2. Molar ellipticity coefficients, [θ], are in degrees, concentration, c, is given in mol·L−1, and 
path length, l, is given in cm, to give units for [θ] of deg·cm2·dmol−1. NMR titrations were performed 
by adding of 10 µL portions of the d6-DMSO in a NMR-tubes containing solutions of the examined 
peptides 1–4 in CDCl3 (c = 2.5 × 10−2 M). The spectra were recorded after each addition and  
d6-DMSO was added until no further change in the chemical shifts of the NHs were observed. CD 
titrations were performed in a similar manner by stepwise addition of DMSO into cuvettes containing 
solutions of the examined peptides 1–4 in CDCl3 (c = 5 × 10−3 M). The mass spectra were acquired 
using 4800 MALDI TOF/TOF-MS Analyzer. Preparation of intact samples. Peptide samples 1–4, each 
were dissolved in deionized water to concentration of 0.05 mg/mL. Volume of 10 µL of each sample 
solution was purified using ZipTip C4 pipette tips (Millipore, Bedford, MA, USA) and dried, then 
dissolved in CHCA matrix (α-cyano-4-hydroxycinnamic acid, 5 mg/mL, Sigma–Aldrich) and dried 
onto the MALDI plate (volume of 1 µL). At the end, 0.05 µg of peptide was deposited onto the 
MALDI plate. MALDI TOF/TOF-MS. For direct profiling and MS/MS fragmentation study of 
peptides a 4800 Plus MALDI TOF/TOF analyzer (Applied Biosystems Inc., Foster City, CA, USA) 
equipped with a 200 Hz, 355 nm Nd:YAG laser was used. Acquisition was performed in positive ion 
reflector mode. Instrument parameters were set using the 4000 Series Explorer software version  
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(V 3.5.3, Applied Biosystems Inc.). Mass spectra were obtained by averaging 1000 laser shots 
covering the mass range between m/z 9 and 4500. MS/MS was achieved by 1 or 2 kV collision induced 
dissociation (CID) in positive ion mode. For both MALDI-TOF MS and MS/MS analysis, CHCA 
matrix was used. Dried purified samples (both intact and derivatized) were diluted in 5 µL of matrix,  
1 µL of mixture was spotted onto the MALDI plate and allowed to dry. 
3.2. General Procedure for the Preparation of Compounds 1 and 2 
Ac-Fca-Pro-OMe (1) and Boc-Fca-Pro-OMe (2). Ac-Fca-OH (200 mg, 0.76 mmol) and Boc-Fca-OH 
(262 mg, 0.76 mmol), prepared by hydrolysis of the fully protected Fca [25], were activated using 
EDC (162 mg, 0.84 mmol) and HOBt (114 mg, 0.84 mmol) in CH2Cl2, respectively. Pro-OMe 
(obtained from HCl·Pro-OMe (254 mg, 1.53 mmol) by treatment with Et3N in CH2Cl2, pH ~ 8) was 
added and the mixtures were stirred at room temperature until complete consumption of the ferrocene 
starting material, as monitored by TLC. The standard work-up (washing with a saturated aqueous 
solution of NaHCO3, 10% aqueous solution of citric acid and brine, drying over Na2SO4 and 
evaporation in vacuo) followed with TLC-purification of the crude products [CH2Cl2:EtOAc = 5:1 (1) 
and CH2Cl2:EtOAc = 10:1 (2)] gave orange resin of 1 (213 mg, 70%) and orange crystals of 2 (274 mg, 
79%), respectively. 
Ac-Fca-Pro-OMe (1). IR (Nujol) νmax 3434 w (NHfree), 3351, 3231 m (NHassoc.), 1741 s (C=OCOOMe), 
1676 s (C=OAc), 1604 s (C=OCONH), 1535 s (amide II) cm−1; Rf = 0.30 (CH2Cl2:EtOAc = 5:1);  
1H- NMR (CDCl3, 600 MHz) δ 8.38 (s, 0.09H, NHcis), 8.23 (s, 0.91H, NHtrans), 4.80-4.78 (m, 1H, 
CHFn), 4.62 (dt, 1H, J1 = 2.9 Hz, J2 = 1.5 Hz, CHFn), 4.60 (m, 1H, CHαPro), 4.60–4.58 (m, 1H, CHFn), 
4.54 (dt, 1H, J1 = 2.7 Hz, J2 = 1.4 Hz, CHFn), 4.40–4.37 (m, 2H, CHFn), 4.07–4.05 (m, 1H, CHFn), 
4.03–4.01 (m, 1H, CHFn), 3.81 (s, 3H, CH3COOMe), 3.79–3.73 (m, 2H, CHδPro), 2.33–2.28 (m, 1H, 
CHβPro), 2.11–2.08 (m, 1H, CHγPro), 2.06 (s, 3H, CH3Ac), 1.99–1.93 (m, 2H, CHβPro+CHγPro); 13C-NMR 
(CDCl3, 150 MHz) δ 173.78 (COCOOMe), 169.94 (COCO-N), 169.69 (COAc), 94.20 (CqFn), 79.92 (CqFn), 
73.22, 71.49, 71.08, 70.46, 66.71, 66.54, 66.18, 64.71 (CHFn trans), 70.46, 70.18, 70.06, 66.71, 66.42 
(CHFn cis), 60.90 (CHαPro cis), 60.15 (CHαPro trans), 52.67 (CH3COOMe cis), 52.53 (CH3COOMe trans), 49.18 
(CH2δPro trans), 47.52 (CH2δPro cis), 29.82 (CH2βPro cis), 29.03 (CH2βPro trans), 25.83 (CH2γPro trans), 23.83 
(CH3Ac), 22.36 (CH2γPro cis); HRMS (MALDI) m/z 398.0939 (calcd for C19H22N2O4Fe, 398.0923). 
Boc-Fca-Pro-OMe (2): mp 125–128 °C. IR (Nujol) νmax 3430 m (NHfree), 3356 sh, 3315 m (NHassoc.), 
1741 sh (C=OCOOMe), 1718 s (C=OBoc), 1604 s (C=OCONH), 1532 s (amide II) cm−1; Rf = 0.50 
(CH2Cl2:EtOAc = 10:1); 1H-NMR (CDCl3, 600 MHz) δ 7.12 (br. s, 0.93H, NHtrans), 6.80 (br. s, 0.07H, 
NHcis), 4.88–4.84 (m, 1H, CHFn), 4.65 (dt, 1H, J1 = 2.7 Hz, J2 = 1.5 Hz, CHFn), 4.62 (dd, 1H,  
J1 = 8.8 Hz, J2 = 6.6 Hz, CHαPro), 4.42–4.37 (m, 2H, CHFn), 4.37–4.34 (m, 1H, CHFn), 4.07–4.03 (m, 
1H, CHFn), 3.98–3.95 (m, 1H, CHFn), 3.87–3.80 (m, 1H, CHδPro), 3.81 (s, 3H, CH3COOMe), 3.77–3.73 
(m, 1H, CHδPro), 2.28–2.24 (m, 1H, CHβPro), 2.16–2.14 (m, 1H, CHγPro), 2.04–1.95 (m, 2H, CHβPro+CHγPro), 
1.49 (s, 9H, CH3Boc); 13C-NMR (CDCl3, 150 MHz) δ 174.01 (COCOOMe), 169.77 (COCO-N), 153.91 
(COBoc), 96.79 (CqFn), 79.80 (CqFn), 76.36 (CqBoc), 72.77, 71.86, 71.22, 70.96, 66.09, 65.45, 64.40, 
62.75 (CHFn trans), 70.64, 70.49, 69.98 (CHFn cis), 60.64 (CHαPro cis), 60.36 (CHαPro trans), 52.57 
(CH3COOMe), 48.77 (CH2δPro trans), 47.50 (CH2δPro cis), 32.03 (CH2βPro cis), 28.58 (CH2βPro trans), 28.57 
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(CH3Boc), 25.98 (CH2γPro trans), 22.17 (CH2γPro cis). HRMS (MALDI) m/z 456.1353 (calcd for 
C22H28N2O5Fe, 456.1342). 
3.3. General Procedure for the Preparation of Compounds 3 and 4 
Boc-Pro-Fca-OMe (3) and Ac-Pro-Fca-OMe (4). HCl·Fca-OMe, obtained from the fully protected Fca 
(500 mg, 1.4 mmol) by action of gaseous HCl in CH2Cl2, was treated with NEt3 to give unstable free 
base [22] which was coupled with Boc-Pro-OH (602 mg, 2.8 mmol) using standard EDC/HOBt 
method. After standard work-up and TLC purification (CH2Cl2-EtOAc = 5:1), yellow crystals of  
Boc-Pro-Fca-OMe (3, 1060 mg, 83%) were obtained. The transformation of Boc-peptide 3 (400 mg, 
0.89 mmol) to Ac-analogue 4 was carried out by action of acetyl chloride (380 μL, 5.34 mmol): the 
free base, obtained via hydrochloride salt provided by deprotection of 3 in the above described manner, 
was cooled at 0 °C and acetyl chloride was dropwise added. After stirring in an ice bath for 15 min, 
TLC indicated no residual starting material remained and the reaction mixture was poured into water 
and extracted with CH2Cl2. The combined organic phases were washed with a brine, dried over 
Na2SO4 and evaporated to dryness in vacuo. The resulting crude product was purified by TLC on 
silicagel (EtOAc) to give orange solid of 4 (325 mg, 92%). 
Boc-Pro-Fca-OMe (3): mp 128–132 °C; IR IR (Nujol) νmax 3419 sh, 3405 m (NHfree), 3290 m, 3234 w 
(NHassoc.), 1706 s (C=OCOOMe), 1694 s (C=OBoc), 1655 s (C=OCONH), 1532 s (amide II) cm−1;  
Rf = 0.33 (CH2Cl2:EtOAc = 5:1); 1H-NMR* (CDCl3, 600 MHz) δ 8.78 (s, 0.66H, NHtrans), 7.53  
(s, 0.33H, NHcis), 4.80–4.77 (m, 0.67H, CHFn trans), 4.76 (dt, 0.66H, J1 = 2.6 Hz, J2 = 1.3 Hz, CHFn 
trans), 4.74 (dt, 0.66H, J1 = 2.7 Hz, J2 = 1.3 Hz, CHFn trans), 4.70 (dt, 0.32H, J1 = 2.5 Hz, J2 = 1.3 Hz, 
CHFn cis), 4.69 (dt, 0.33H, J1 = 2.4 Hz, J2 = 1.2 Hz, CHFn cis), 4.64 (dt, 0.32H, J1 = 2.7 Hz, J2 = 1.4 Hz, 
CHFn cis), 4.49 (dt, 0.34H, J1 = 2.7 Hz, J2 = 1.4 Hz, CHFn cis), 4.48–4.45 (m, 0.64H, CHFn trans),  
4.44–4.42 (m, 0.34H, CHFn cis), 4.40–4.38 (m, 0.33H, CHFn cis), 4.38–4.37 (m, 0.65H, CHFn trans),  
4.36–4.33 (m, 1.4H, CHαPro trans+CHFn trans), 4.26 (dd, 0.33H, J1 = 8.7 Hz, J2 = 3.4 Hz, CHαPro cis),  
4.11–4.09 (m, 0.32H, CHFn cis), 4.09–4.07 (m, 0.32H, CHFn cis), 4.02–3.99 (m, 1.32H, CHFn trans), 3.79  
(s, 0.98H, CH3COOMe cis), 3.78 (s, 1.94H, CH3COOMe trans), 3.62 (ddd, 0.35H, J1 = 10.9 Hz, J2 = 7.4 Hz,  
J3 = 3.6 Hz, CHδPro cis), 3.52-3.46 (m, 0.36H, CHδPro cis), 3.44 (ddd, 0.70H, J1 = 10.3 Hz, J2 = 7.2 Hz,  
J3 = 2.8 Hz, CHδPro trans), 3.28 (td, 0.7H, J1 = 10.2 Hz, J2 = 7.2 Hz, CHδPro trans), 2.43–2.38 (m, 0.70H, 
CHβPro trans), 2.29–2.21 (m, 0.31H, CHβPro cis), 2.21–2.15 (m, 0.34H, CHβPro cis), 2.00–1.90 (m, 2.07H, 
CHγPro trans + CHγPro cis), 1.90-1.83 (m, 0.63H, CHβPro trans), 1.48 (s, 5.97H, CH3Boc trans), 1.45 (s, 3.08H, 
CH3Boc cis). 13C-NMR* (CDCl3, 150 MHz) δ 172.39 (COCOOMe cis), 172.21 (COCOOMe trans), 171.52 
(COCO-NH cis), 170.24 (COCO-NH trans), 156.34 (COBoc trans), 155.06 (COBoc cis), 95.30 (CqFn trans), 93.94 
(CqFn cis), 81.19 (CqFn), 80.91 (CqBoc trans), 73.04, 71.10, 70.69, 66.54, 66.33, 62.54, 62.40, (CHFn trans), 
72.74, 71.44, 70.95, 66.84, 66.82, 63.77, 62.98 (CHFn cis), 72.90 (CHFn), 61.59 (CHαPro cis), 59.83 
(CHαPro trans), 52.25 (CH3COOMe cis), 52.08 (CH3COOMe trans), 47.17 (CH2δPro), 31.21 (CH2βPro cis), 28.33 
(CH3Boc), 27.21 (CH2βPro trans), 24.71 (CH2γPro trans), 23.77 (CH2γPro cis); HRMS (MALDI) m/z 456.136 
(calcd for C22H28N2O5Fe, 456.1342). * Due to the poor signal resolution at the higher temperatures, 
NMR spectra were recorded at 228 K. 
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Ac-Pro-Fca-OMe (4): mp 136–138 °C; IR IR (Nujol) νmax 3416 w (NHfree), 3272 m, 3229 m (NHassoc.), 
1709 s (C=OCOOMe), 1690 s (C=OAc), 1623 s (C=OCONH), 1563 s (amide II) cm−1; Rf = 0.22 
(CH2Cl2:EtOAc = 5:1); 1H-NMR (CDCl3, 600 MHz) δ 8.81 (s, 0.92H, NHtrans), 7.29 (s, 0.08H, NHcis), 
4.75–4.72 (m, 2H, CHFn), 4.67–4.65 (m, 2H, CHFn+CHαPro), 4.63 (m, 0.06H, CHFn cis), 4.56 (dt, 0.93H, 
J1 = 2.7 Hz, J2 = 1.4 Hz, CHFn trans), 4.54–4.53 (m, 0.06H, CHFn cis), 4.40–4.39 (m, 0.16H, CHFn cis), 
4.38–4.36 (m, 1.87H, CHFn trans), 4.10–4.08 (m, 0.14H, CHFn cis), 4.01–3.99 (m, 1.86H, CHFn trans), 3.79 
(s, 3H, CH3COOMe), 3.63 (ddd, 1H, J1= 10.3 Hz, J2 = 9.1 Hz, J3 = 3.0 Hz, CHδPro), 3.45 (td, 1H,  
J1 = 9.9 Hz, J2 = 7.0 Hz, CHδPro), 2.59–2.56 (m, 1H, CHβPro), 2.20–2.15 (m, 1H, CHγPro), 2.18 (s, 3H, 
CH3Ac), 2.06–2.01 (m, 1H, CHγPro), 1.87–1.81 (m, 1H, CHβPro); 13C-NMR (CDCl3, 150 MHz) δ 171.77 
(COCOOMe), 171.67 (COCO-NH), 169.30 (COAc), 95.78 (CqFn), 72.29 (CqFn), 72.55, 72.53, 71.41, 71.22, 
66.33, 66.27, 63.11, 62.99, (CHFn trans), 71.73, 71.35, 66.85, 66.72, 64.08, 63.65 (CHFn cis), 60.15 
(CHαPro), 51.94 (CH3COOMe cis), 51.68 (CH3COOMe trans), 48.51 (CH2δPro trans), 47.11 (CH2δPro cis), 31.36 
(CH2βPro cis), 26.81 (CH2βPro trans), 25.23 (CH3Ac), 23.22 (CH2γPro trans), 22.71 (CH2γPro cis); HRMS 
(MALDI) m/z 398.0936 (calcd for C19H22N2O4Fe, 398.0923). 
3.4. Crystallography 
Crystals suitable for single-crystal X-ray diffraction analysis were grown from CDCl3 by slow 
evaporation of the solvent at low temperature (277 K). Single crystal measurements were performed on 
an Oxford Diffraction Xcalibur Nova R (microfocus Cu tube) at room temperature [293(2) K]. 
Program package CrysAlis PRO [76] was used for data reduction. The structures were solved using 
SHELXS97 [77] and refined with SHELXL97 [77]. The models were refined using the full-matrix 
least squares refinement; all non-hydrogen atoms were refined anisotropically. Hydrogen atoms bound 
to C atoms were modelled as riding entities using the AFIX command. Molecular geometry 
calculations were performed by PLATON [78], and molecular graphics were prepared using  
ORTEP-3 [79], and CCDC-Mercury [80]. Crystallographic and refinement data for the structures 
reported in this paper are shown in Table 7. 
Table 7. Crystallographic, data collection and structure refinement details. 
Compound Boc-Pro-Fca-OMe (3) 
Empirical formula C22H28FeN2O5 
Formula wt./g·mol−1 456.31 
Crystal dimensions/mm 0.08 × 0.06 × 0.03 
Space group P 21 
a/Å 10.951(5) 
b/Å 8.571(5) 
c/Å 11.944(5) 
α/° 90 
β/° 107.315(5) 
γ/° 90 
Z 2 
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Table 7. Cont. 
Compound Boc-Pro-Fca-OMe (3) 
V/Å3 1070.3(9) 
Dcalc/g cm−3 1.416 
µ/mm−1 5.954 
Θ range/° 3.88–75.86 
T/K 293(2) 
Radiation vawelength 1.54179 (CuKα) 
Diffractometer type Xcalibur Nova 
Range of h, k, l 
−13 < h < 13;  
−10 < k < 10;  
−11 < l < 14 
Reflections collected 5054 
Independent reflections 3430 
Observed reflections  
(I ≥ 2σ) 3108 
Absorption correction Multi-scan 
Rint 0.0507 
R (F) 0.1024 
Rw (F2) 0.2806 
Goodness of fit 1.268 
H atom treatment Constrained 
No. of parameters 271 
No. of restraints 1 
Δρmax, Δρmin (eÅ−3) 1.3091; −1.272 
CCDC 1011219 contains the supplementary crystallographic data for this paper. This supplementary 
crystallographic data can be obtained free of charge via www.ccdc.cam.ac.uk/conts/retrieving.html  
(or from the Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, UK; 
Fax: +44 1223 336033; or deposit@ccdc.cam.ac.uk).  
3.5. Biological Evaluation  
3.5.1. Cell Culture and Stock Solutions 
MCF-7 cell line derived from human breast adenocarcinoma (ATCC No. HTB-22) and HeLa cell 
line derived from the human cervical adenocarcinoma (ATCC No. CCL-2) were obtained from the 
Ruđer Bošković Institute, Zagreb, Croatia. Both cell lines were maintained in Dulbecco’s modified 
Eagle’s medium (DMEM, Gibco, Paisley, UK) supplemented with 10% heat-inactivated fetal bovine 
serum (FBS, Gibco) in the incubator at 310 K in humidified atmosphere with 5% CO2. Stock solutions 
of tested compounds 1–4 were prepared as 10 mM solutions in ethanol (EtOH) and stored at 277 K. 
The stock solutions were further diluted with culture medium prior to use in cytotoxicity assay. 
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3.5.2. Cytotoxicity Assay 
The effect of the synthesised compounds 1–4 on cell proliferation was examined by the WST-1 assay 
(Roche, Mannheim, Germany), modification of classical MTT test [81]. MCF-7 and HeLa cells from the 
exponential growth phase were trypsinized and plated out in 96-well plates at a density of 5 × 104 cells/well 
in 100 µL of media. After overnight cell growth, the media was replaced with fresh one containing 
different concentrations of individual compound (1–500 µM). The appropriate volume of EtOH was 
added to control cells, but the final concentration of EtOH in the control and treated cells was less than 
0.2% and had no interference with the biological activities tested. Following exposure for 72 h, 10 µL 
of tetrazolium salt WST-1 {4-[3-(4-Iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene 
disulfonate) was added to each well and cells were incubated for the further 4 h. The absorbance was 
measured at 450 nm on the microplate reader (Tecan, Mannedorf, Switzerland). The experiments  
were performed three times with four parallels for each concentration and data were expressed as the 
means ± S.D. Cell viability was presented as percentage of treated cells vs. control cells by setting the 
viability of control cell as 100%. The IC50 values, defined as the concentration of tested compound that 
resulted with 50% growth inhibition, were calculated from the dose-response curves using equations of 
best-fitted trend-lines. 
3.5.3. Staining with Crystal-Violet 
Light microscopy was used to observe the morphological changes during the treatment. MCF-7 
cells (1 × 105 cells/mL) were seeded in the plate with 6 wells and after overnight cell growth exposed 
to the highest concentration of tested compounds (500 µM) for 72 h. The cells were then washed with 
PBS and stained with crystal-violet dye solution (Sigma–Aldrich, St. Louis, MO, USA). Images of 
control and treated MCF-7 cells were taken using an inverted microscope (Carl Zeiss, Göttingen, 
Germany) and Dino-Eye digital camera. 
4. Conclusions  
Four novel conjugates 1–4 of Fca and proline have been prepared. Their conformations in solution 
have been elucidated using IR, NMR and CD spectroscopic methods. In addition, the crystal structure 
of peptide 3 has been resolved.  
Due to lack of the amide proton at the lower Cp ring of 1 and 2, their stabilization by intramolecular 
hydrogen bonding has been provided through interchain interaction of NHFca and OCPro (9-membered 
IHB ring) which corresponds to IHB pattern of the type A presented in their alanine analogues III. 
Hence, the conformation B founded in III has not been realized. The alteration of peptides 1 and 2 into 
3 and 4, respectively, notably influenced their conformational settings. The same donor (NHFca) and 
acceptor (OCPro) were engaged in hydrogen bonding, but in a different manner, i.e., an intrachain 
IHBs have been founded. With respect to their alanine analogues IV, stabilized by three alternative 
patterns of hydrogen bonding, peptides 3 and 4 have been adopted 7-membered IHB ring (γ-turn) 
correlated to IVA conformation. Although it has been shown that hydrogen bonding is somewhat 
difficult in the presence of the bulky Boc group, its replacement with an Ac group did not cause 
significant conformational changes. 
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The biological evaluation of peptides 1–4, performed with regard to antiproliferative effect on 
MCF-7 and HeLa cell line, has been revealed no or rather modest cytotoxic effects only at the maximal 
tested concentration in the high micromolar range. Those results are not satisfactory if we consider the 
tested compounds as promising cytotoxic agents candidates, but are valuable as a guideline to direct 
the synthesis of the corresponding analogues with improved biological properties. The goal of the 
presented biological evaluation was to find lead structures as a starting point for future search of 
optimized drug candidates what will surely be our further scientific interest. 
Supplementary Materials 
Supplementary materials (HRMS, 1H and 13C NMR spectra of novel compounds 1–4,  
1H NMR titration of compounds 1–4 with DMSO in CDCl3, Variable-temperature  
1H NMR spectra of 1–4 and checkCIF_PLATON report of compound 3) can be accessed at: 
http://www.mdpi.com/1420-3049/19/8/12852/s1.  
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